Luis Rios

Luis Rios is a molecular scientist with over a decade of neuroscience, metabolism, and drug discovery expertise. With three years of experience in venture capital, Luis served as a consultant and venture partner at Vine Ventures, Longitude Capital, and Healthspan Capital, where he focused on biotech investments in therapeutics, psychedelics, longevity, and neurotechnology. During his PhD at Stanford University, Luis made a groundbreaking discovery of a novel anti-inflammatory agent with demonstrated efficacy in sepsis and neurodegeneration animal models. He also contributed to building ImmuneAge Bio, a company pioneering bone marrow rejuvenation therapies, and founded Fission Bio, a company developing therapeutics for inflammatory disease. Luis is now running AI-enabled in silico drug discovery services as the COO and Founding Scientist of KlyneAI.